Literature DB >> 7961695

The allosteric site of human liver fructose-1,6-bisphosphatase. Analysis of six AMP site mutants based on the crystal structure.

M Gidh-Jain1, Y Zhang, P D van Poelje, J Y Liang, S Huang, J Kim, J T Elliott, M D Erion, S J Pilkis, M Raafat el-Maghrabi.   

Abstract

The molecular structure of human liver fructose-1,6-bisphosphatase complexed with AMP was determined by x-ray diffraction using molecular replacement, starting from the pig kidney enzyme AMP complex. Of the 34 amino acid residues which differ between these two sequences, only one interacts with AMP; Met30 in pig kidney is Leu30 in human liver. From this analysis, six sites in which side chains of amino acid residues are in contact with AMP, Ala24, Leu30, Thr31, Tyr113, Arg140, and Met177, were mutated by polymerase chain reaction. The wild-type and mutant forms were expressed in Escherichia coli, purified, and their kinetic properties determined. Circular dichroism spectra of the mutants were indistinguishable from that of the wild-type enzyme. Kinetic analyses revealed that all forms had similar turnover numbers, Km values for fructose 2,6-bisphosphate, and inhibition constants for fructose 2,6-bisphosphate. Apparent Ki values for AMP inhibition of the Leu30 --> Phe and Met177 --> Ala mutants were similar to those of the wild-type enzyme, but the apparent Ki values for the Arg140 --> Ala and Ala24 --> Phe mutants were 7-to 20-fold higher, respectively. The Thr31 --> Ser mutant exhibited a 5-fold increase in apparent Ki for AMP, while mutation of Thr31 to Ala increased the apparent Ki 120-fold. AMP inhibition of the Tyr113 --> Phe mutant was undetectable even at millimolar AMP concentrations. Fructose 2,6-bisphosphate potentiated AMP inhibition of the mutants to the same extent as for the wild-type enzyme, except in the case of the Thr31 --> Ala and Tyr113 --> Phe mutants. Thus, the Met177 --> Ala mutant suggests that the side chain beyond C alpha is not needed for AMP binding, and that the Leu30 --> Phe mutant preserves the AMP contacts with these side chains. Thr31, Tyr113, and Arg140 form key hydrogen bonds to AMP consistent with strong side chain interactions in the wild-type enzyme. Finally, the absence of any effect of fructose 2,6-bisphosphate on AMP inhibition observed in the Thr31 --> Ala mutant may be an important clue relating to the mechanism of synergism of these two inhibitors.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7961695

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  14 in total

1.  Designing inhibitors against fructose 1,6-bisphosphatase: exploring natural products for novel inhibitor scaffolds.

Authors:  Sabrina Heng; Katharine M Harris; Evan R Kantrowitz
Journal:  Eur J Med Chem       Date:  2010-01-13       Impact factor: 6.514

2.  Contact rearrangements form coupled networks from local motions in allosteric proteins.

Authors:  Michael D Daily; Tarak J Upadhyaya; Jeffrey J Gray
Journal:  Proteins       Date:  2008-04

3.  Crystal structures of the active site mutant (Arg-243-->Ala) in the T and R allosteric states of pig kidney fructose-1,6-bisphosphatase expressed in Escherichia coli.

Authors:  B Stec; R Abraham; E Giroux; E R Kantrowitz
Journal:  Protein Sci       Date:  1996-08       Impact factor: 6.725

4.  Characterization of the allosteric binding pocket of human liver fructose-1,6-bisphosphatase by protein crystallography and inhibitor activity studies.

Authors:  L F Iversen; M Brzozowski; S Hastrup; R Hubbard; J S Kastrup; I K Larsen; L Naerum; L Nørskov-Lauridsen; P B Rasmussen; L Thim; F C Wiberg; K Lundgren
Journal:  Protein Sci       Date:  1997-05       Impact factor: 6.725

5.  MB06322 (CS-917): A potent and selective inhibitor of fructose 1,6-bisphosphatase for controlling gluconeogenesis in type 2 diabetes.

Authors:  Mark D Erion; Paul D van Poelje; Qun Dang; Srinivas Rao Kasibhatla; Scott C Potter; M Rami Reddy; K Raja Reddy; Tao Jiang; William N Lipscomb
Journal:  Proc Natl Acad Sci U S A       Date:  2005-05-23       Impact factor: 11.205

6.  Novel FBP1 gene mutations in Arab patients with fructose-1,6-bisphosphatase deficiency.

Authors:  Muhammad Faiyaz-Ul-Haque; Mohammed Al-Owain; Fouad Al-Dayel; Zuhair Al-Hassnan; Hamad Al-Zaidan; Zuhair Rahbeeni; Moeen Al-Sayed; Ameera Balobaid; Ahmad Cluntun; Mohamed Toulimat; Hala Abalkhail; Iskra Peltekova; Syed H E Zaidi
Journal:  Eur J Pediatr       Date:  2009-03-04       Impact factor: 3.183

7.  In silico identification of structure requirement for novel thiazole and oxazole derivatives as potent fructose 1,6-bisphosphatase inhibitors.

Authors:  Ming Hao; Xiaole Zhang; Hong Ren; Yan Li; Shuwei Zhang; Fang Luo; Mingjuan Ji; Guohui Li; Ling Yang
Journal:  Int J Mol Sci       Date:  2011-11-18       Impact factor: 5.923

8.  Enzymatic Characterization of Fructose 1,6-Bisphosphatase II from Francisella tularensis, an Essential Enzyme for Pathogenesis.

Authors:  Hiten J Gutka; Nina M Wolf; Jasper Marc G Bondoc; Farahnaz Movahedzadeh
Journal:  Appl Biochem Biotechnol       Date:  2017-05-25       Impact factor: 2.926

9.  Crystal structures of human muscle fructose-1,6-bisphosphatase: novel quaternary states, enhanced AMP affinity, and allosteric signal transmission pathway.

Authors:  Rong Shi; Ze-Yong Chen; Dao-Wei Zhu; Chunmin Li; Yufei Shan; Genjun Xu; Sheng-Xiang Lin
Journal:  PLoS One       Date:  2013-09-27       Impact factor: 3.240

10.  Structures of Leishmania Fructose-1,6-Bisphosphatase Reveal Species-Specific Differences in the Mechanism of Allosteric Inhibition.

Authors:  Meng Yuan; Montserrat G Vásquez-Valdivieso; Iain W McNae; Paul A M Michels; Linda A Fothergill-Gilmore; Malcolm D Walkinshaw
Journal:  J Mol Biol       Date:  2017-09-04       Impact factor: 5.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.